







an Open Access Journal by MDPI

Targeted Therapies for EGFR in Non-small Cell Lung Cancer

Guest Editor:

Dr. Federico Pio Fabrizio

Laboratory of Oncology, Scientific Institute for Research and Health Care (IRCCS), San Giovanni Rotondo, Foggia, Italy

Deadline for manuscript submissions:

31 December 2024

Message from the Guest Editor

Dear Colleagues,

Submissions are open for a Special Issue of Cancers on "Targeted Therapies for EGFR in Non-Small Cell Lung Cancer." We seek original research, and reviews on EGFR mutations in NSCLC, covering molecular mechanisms, targeted therapy development, resistance mechanisms, and clinical trial evidence. Contributions from lung cancer researchers and clinicians are encouraged. Rigorous peer review will ensure scientific quality. Let's advance our understanding of EGFR-targeted therapies in NSCLC and develop more effective treatments. Looking forward to your valuable submissions.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us